OncoMatch/Clinical Trials/NCT06624085
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Is NCT06624085 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for lymphoma.
Treatment: Glofitamab · Tocilizumab · Obinutuzumab · Gemcitabine · Oxaliplatin — The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
At least one prior line of systemic therapy
Cannot have received: glofitamab or other bispecific antibodies targeting both CD20 and CD3
Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3
Cannot have received: gemcitabine (gemcitabine)
Prior treatment with gemcitabine
Cannot have received: oxaliplatin (oxaliplatin)
Prior treatment with oxaliplatin
Cannot have received: monoclonal antibody
Exception: within 4 weeks prior to first study treatment
Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment
Cannot have received: radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent
Exception: within 2 weeks prior to first study treatment
Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to first study treatment
Cannot have received: systemic immunosuppressive medications
Exception: within 4 weeks prior to first dose of study treatment
Prior treatment with systemic immunosuppressive medications within 4 weeks prior to first dose of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC San Diego Moores Cancer Center · La Jolla, California
- Saddleback Memorial Medical Center · Laguna Hills, California
- University of California Los Angeles (UCLA) - Cancer Care - Santa Monica · Santa Monica, California
- Georgetown University · Washington D.C., District of Columbia
- AdventHealth Cancer Institute · Orlando, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06624085 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior glofitamab or other bispecific antibodies targeting both CD20 and CD3, gemcitabine, oxaliplatin disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages